- Home
- PPBT vs CANF Comparison
PPBT vs CANF Comparison
Compare PPBT & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- CANF
- Stock Information
- Founded
- PPBT 2010
- CANF 1994
- Country
- PPBT Israel
- CANF Israel
- Employees
- PPBT N/A
- CANF N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- PPBT Health Care
- CANF Health Care
- Exchange
- PPBT Nasdaq
- CANF Nasdaq
- Market Cap
- PPBT 7.1M
- CANF 7.9M
- IPO Year
- PPBT N/A
- CANF N/A
- Fundamental
- Price
- PPBT $2.73
- CANF $1.17
- Analyst Decision
- PPBT Strong Buy
- CANF Strong Buy
- Analyst Count
- PPBT 1
- CANF 2
- Target Price
- PPBT $33.00
- CANF $14.00
- AVG Volume (30 Days)
- PPBT 16.2K
- CANF 412.3K
- Earning Date
- PPBT 05-20-2025
- CANF 05-06-2025
- Dividend Yield
- PPBT N/A
- CANF N/A
- EPS Growth
- PPBT N/A
- CANF N/A
- EPS
- PPBT N/A
- CANF N/A
- Revenue
- PPBT N/A
- CANF $674,000.00
- Revenue This Year
- PPBT N/A
- CANF $461.72
- Revenue Next Year
- PPBT N/A
- CANF N/A
- P/E Ratio
- PPBT N/A
- CANF N/A
- Revenue Growth
- PPBT N/A
- CANF N/A
- 52 Week Low
- PPBT $2.00
- CANF $1.22
- 52 Week High
- PPBT $20.60
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- PPBT 51.95
- CANF 37.12
- Support Level
- PPBT $2.67
- CANF $1.14
- Resistance Level
- PPBT $2.75
- CANF $1.27
- Average True Range (ATR)
- PPBT 0.21
- CANF 0.12
- MACD
- PPBT 0.04
- CANF -0.02
- Stochastic Oscillator
- PPBT 67.19
- CANF 4.46
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).